Tobira Therapeutics presented positive results from an evaluation of cenicriviroc (CVC) in two animal models of liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) annual meeting (The Liver Meeting®) in Washington, DC. CVC is a novel, oral, once-daily, dual CCR2 and CCR5 antagonist in late-stage clinical development for the treatment of HIV infection as part of fixed-dose combination regimens, and in planning for clinical development in liver fibrosis and other diseases in which antagonism of CCR2 and CCR5 may have a therapeutic effect.
Help employers find you! Check out all the jobs and post your resume.
